China Blood Product Industry Report, 2020-2027
  • Mar.2021
  • Hard Copy
  • USD $3,600
  • Pages:180
  • Single User License
    (PDF Unprintable)       
  • USD $3,400
  • Code: YG001
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $5,000
  • Hard Copy + Single User License
  • USD $3,800

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which has further opened up the blood product market. In 2020, the lot release volume of blood products in China sustained growth, hitting 101.31 million bottles, a year-on-year upsurge of 12.7%. 

Wherein, the lot release volume of human albumin rose 14.78% on an annualized basis, making up 60%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 12.92% in the total showed a year-on-year increase of 11.78%; that of human tetanus immunoglobulin soared by 76.7% and accounted for 6.9%; other products like human fibrinogen, human prothrombin complex and human coagulation factor VIII took relatively low shares.          

BLOOD 1_副本.png

The Health Commission of Yunnan Province proposed to set up 24 plasma collection stations (adding 20 new ones based on the 4 pilot ones) across the province, according to the Plan of Yunnan Province for Setting up Plasma Collection Stations (2020-2023) (Exposure Draft) it issued in December 2020. Currently, Shanghai Blood Products under Beijing Tiantan Biological Products has 2 pilot stations operated in Yunnan, having collected a total of around 42 tons. Also, the document indicates blood product companies that construct production bases in Yunnan will be given priority to build. With its plasma station expansion plan, Yunnan may set the pace in loosening the restrictions on new plasma stations. On one estimate, China had boasted 273 plasma collection stations by the end of 2020.

In 2020, the pandemic suspended plasma collection in China for two months, stopping collection volume growth. Chinese Academy of Medical Sciences predicted a like-on-like slump of 22%, or 1,000 tons, in plasma collection volume in the first half of 2020.

Companies with more plasma stations, such as Beijing Tiantan Biological Products, Shanghai RAAS Blood Products, China Biologic Products and Hualan Biological Engineering gather pace and will scramble for larger shares on the strength of their great ability to collect plasma, promising their far higher industry status. In 2019, Beijing Tiantan Biological Products, Hualan Biological Engineering, China Biologic Products and Shanghai RAAS Blood Products took a higher combined market share of up to 34.47%.

Blood 2_副本.png

In recent years, there were an increasing number of mergers and acquisitions among blood products companies in China. Leaders roared ahead mainly by way of mergers and acquisitions, an expansion model supplemented by self-built plasma stations. Mergers and acquisitions have been a key part of their long-term strategic plans.

On January 28, 2020, Southern Shuanglin Bio-Pharmacy made an announcement that it would merge with Harbin Pacific Biopharmaceutical and restructure it, and raise funds. Southern Shuanglin Bio-Pharmacy now has 13 plasma collection stations, collecting roughly 400 tons in 2019, compared with Harbin Pacific Biopharmaceutical which owns 10 stations collecting 240 tons in 2019. Moreover, Southern Shuanglin Bio-Pharmacy and Xinjiang Deyuan Bioengineering forged a strategic partnership in which Xinjiang Deyuan Bioengineering promises to provide over 180-ton plasma for Southern Shuanglin Bio-Pharmacy every year, totaling more than 900 tons for the five years to come. Southern Shuanglin Bio-Pharmacy is thus expected to be a first-echelon player in the industry. 

China Blood Product Industry Report, 2020-2027 highlights the following:
20120114.gifChina blood product industry (policy, status quo, market structure, supply & demand, market size, competitive pattern);
20120114.gifChina blood product market segments (status quo, bid price, competitive pattern);
20120114.gif13 blood product companies (operation, revenue structure, gross margin, blood product business, etc.);
20120114.gifSummary and forecast.

1. Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. China Blood Product Market
2.1 Policies
2.2 Status Quo
2.3 Market Structure
2.4 Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competitive Pattern

3. China Blood Product Market Segments
3.1 Human Albumin
3.1.1 Status Quo
3.1.2 Bid Price
3.1.3 Market Structure
3.1.4 Competitive Pattern
3.1.5 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Status Quo 
3.2.2 Bid Price
3.2.3 Competitive Pattern
3.2.4 Prospects
3.3 Coagulation Factor VIII
3.3.1 Status Quo
3.3.2 Bid Price
3.3.3 Competitive Pattern
3.3.4 Prospects
3.4 Human Hepatitis B Immunoglobulin
3.4.1 Status Quo
3.4.2 Bid Price
3.4.3 Competitive Pattern
3.5 Human Immunoglobulin
3.5.1 Status Quo
3.5.2 Bid Price 
3.5.3 Competitive Pattern
3.6 Human Prothrombin Complex
3.6.1 Status Quo
3.6.2 Bid Price
3.6.3 Competitive Pattern
3.7 Human Tetanus Immunoglobulin
3.7.1 Status Quo
3.7.2 Bid Price
3.7.3 Competitive Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Status Quo
3.8.2 Bid Price
3.8.3 Competitive Pattern 

4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd. 
4.2 Hualan Biological Engineering Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Chengdu Rongsheng
4.4.8 Dynamics
4.5 Guangdong Shuanglin Bio-Pharmacy 
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 R&D Investment
4.5.5 Blood Products Business
4.5.6 Dynamics 
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Investment
4.6.6 Blood Products Business
4.6.7 Dynamics
4.7 Weiguang Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D Investment
4.7.6 Blood Products Business
4.7.7 Development Strategy
4.8 Beijing Bohui Innovation Technology
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D Investment
4.8.6 Blood Products Business
4.8.7 Development Strategy
4.8.8 Dynamics
4.9 Wuhan ZhongyuanRuide Biological Products Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Blood Products Business
4.10 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.10.1 Profile
4.10.2 Blood Products Business
4.10.3 Development Strategy
4.11 Shanxi Kangbao Biological Product Co., Ltd.
4.11.1 Profile
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.1 Profile
4.12.2 Blood Products Business
4.13 Nanyue Biopharming Corporation Ltd.
4.13.1 Profile
4.13.2 Blood Products Business
4.13.3 Development Strategy

5. Summary and Forecast
5.1 Summary
5.2 Development Trends
5.2.1 The Industry Continues to Boom
5.2.2 Industry Integration Speeds Up, Concentration Rises Further
5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.4 Plasma Collection Volume Increases Progressively
5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness, Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.6 Downstream Demand Stimulates the Industry
5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Growth of the Industry
5.2.8 COVID-19 Pandemic Brings Development Opportunities to Domestic Companies
Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison of Recombinant Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs & Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1986-2020
Development History of China Blood Product Industry
Comparison between China and the United States in Per Capita Consumption of Main Blood Products
Lot Release Volume of Major Blood Products in China, 2014-2020
Structure of Blood Products in China (by Lot Release Volume), 2020
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth in China, 2008-2020
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2019
Plasma Collection Volume and YoY Growth in China, 2008-2019
Plasma Collection Volume Structure of Major Blood Product Enterprises in China, 2018-2019 
Comparison of Blood Products Listed in National Medical Insurance Catalogue, 2017 vs 2009
Plasma Supply and Demand in China, 2015-2025E
Comparison of Cap-lift Prices and Original Highest Retail Prices of Blood Products
Market Size of China Blood Product Industry, 2010-2020
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, as of Dec. 2019
Main Products of Major Blood Product Producers in China
Revenue of Major Blood Product Enterprises in China, 2013-2020
Net Income of Major Blood Product Enterprises in China, 2013-2020
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2020
Market Share of China Blood Product Industry (by Enterprise), 2018
Market Share of China Blood Product Industry (by Enterprise), 2019
Lot Release Volume and YoY Growth of Human Albumin in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2019
Average Successful Bid Prices for Human Albumin in China, 2017-2020
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2020
Lot Release Volume Structure of Human Albumin in China (by Enterprise), 2018
Lot Release Volume Structure of Human Albumin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Albumin in China (by Enterprise), 2020 
Major Enterprises’ Deployments in Recombinant Human Albumin in China
Lot Release Volume of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2010-2020 
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2019
Average Successful Bid Prices for Human Immunoglobulin (pH4) for Intravenous Injection in China, 2016-2020 
Lot Release Volume Structure of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Enterprise), 2018 
Lot Release Volume Structure of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Enterprise), 2019 
Lot Release Volume Structure of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Enterprise), 2020 
Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
Lot Release Volume and YoY Growth of Blood Coagulation Factor VIII in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2019
Lot Release Volume Structure of Blood Coagulation Factor VIII in China (by Enterprise), 2018
Lot Release Volume Structure of Blood Coagulation Factor VIII in China (by Enterprise), 2019  
Lot Release Volume Structure of Blood Coagulation Factor VIII in China (by Enterprise), 2020
Comparison between China and the United States in Per Capita Consumption of Coagulation Factor VIII
Coagulation Factor VIII R&D Progress of Major Blood Product Enterprises in China, as of 2019H1
Lot Release Volume and YoY Growth of Human Hepatitis B Immunoglobulin in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Hepatitis B Immunoglobulin, 2019 
Lot Release Volume Structure of Human Hepatitis B Immunoglobulin in China (by Enterprise), 2018   
Lot Release Volume Structure of Human Hepatitis B Immunoglobulin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Hepatitis B Immunoglobulin in China (by Enterprise), 2020
Lot Release Volume and YoY Growth of Human Immunoglobulin in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin, 2019
Lot Release Volume Structure of Human Immunoglobulin in China (by Enterprise), 2018  
Lot Release Volume Structure of Human Immunoglobulin in China (by Enterprise), 2019 
Lot Release Volume Structure of Human Immunoglobulin in China (by Enterprise), 2020
Lot Release Volume and YoY Growth of Human Prothrombin Complex in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Prothrombin Complex, 2019
Lot Release Volume Structure of Human Prothrombin Complex in China (by Enterprise), 2018
Lot Release Volume Structure of Human Prothrombin Complex in China (by Enterprise), 2019 
Lot Release Volume Structure of Human Prothrombin Complex in China (by Enterprise), 2020 
Lot Release Volume and YoY Growth of Human Tetanus Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Tetanus Immunoglobulin, 2019
Lot Release Volume Structure of Human Tetanus Immunoglobulin in China (by Enterprise), 2018 
Lot Release Volume Structure of Human Tetanus Immunoglobulin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Tetanus Immunoglobulin in China (by Enterprise), 2020
Cases, Deaths and Mortality of Rabies in China, 2013-2020
Lot Release Volume and YoY Growth of Human Rabies Immunoglobulin in China, 2010-2020 
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Rabies Immunoglobulin, 2019
Lot Release Volume Structure of Human Rabies Immunoglobulin in China (by Enterprise), 2018
Lot Release Volume Structure of Human Rabies Immunoglobulin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Rabies Immunoglobulin in China (by Enterprise), 2020
Product Line of CBPO
Equity Structure of China Biologic Products Holdings
Revenue and Operating Income of CBPO, 2015-2020
Revenue Breakdown of CBPO (by Product), 2012-2020
Revenue Structure of CBPO (by Product), 2012-2020
Gross Margin of CBPO, 2012-2020 
R&D Costs and % of Total Revenue of CBPO, 2012-2020
CBPO’s Products under Research and R&D Process by the end of 2019
Main Products in R&D Pipeline of Beijing TianXinFu Medical Appliance
Lot Release Volume of Blood Products of CBPO, 2016-2020 
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Dec. 2019
Equity Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Dec. 2019
Equity Structure of Xi'an Huitian Blood Products 
Main Plasma Collection Stations of Xi'an Huitian Blood Products as of Dec. 2019
Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2017-2020
Revenue and Net Income of Hualan Biological Engineering, 2013-2020
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2020
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2020
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2020
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2020
Category and Specification of Blood Products of Hualan Biological Engineering
Output, Sales Volume and Inventory of Blood Products of Hualan Biological Engineering, 2016-2019
Hualan Biological Engineering’s Revenue from Blood Product Business and % of Total Revenue, 2013-2020
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2020
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2020
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2020
Revenue Structure of Shanghai RAAS Blood Products (by Product), 2013-2020
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2020
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2020
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2020
Shanghai RAAS Blood Products’ R&D Costs and % of Total Revenue, 2013-2020
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Output, Sales Volume and Inventory of Blood Products of Shanghai RAAS Blood Products, 2016-2019
Revenue and Net Income of Tiantan Biological Products, 2013-2020
Revenue Breakdown of Tiantan Biological Products (by Product), 2013-2020
Revenue Structure of Tiantan Biological Products (by Product), 2013-2020
Gross Margin of Tiantan Biological Products (by Product), 2013-2020
Tiantan Biological Products’ R&D Costs and % of Total Revenue, 2013-2020
Tiantan Biological Products’ R&D Input in Major Drugs and % of Total Revenue, 2019 
Progress of Major R&D Projects of Tiantan Biological Products, by the End of 2019
Tiantan Biological Products’ Major Blood Products Subsidiaries and Its Stake in Them 
Production and Sales of Main Blood Products of Tiantan Biological Products, 2019
Lot Release Volume of Main Blood Products of Tiantan Biological Products, 2015-2020 
Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2020
Uses of Funds Tiantan Biological Products Raised by Non-public Offering of A Shares in Oct. 2020
Blood Product Clinical Research Projects of Chengdu Rongsheng Pharmaceutical
Structure of Investments in Blood Product Clinical Research Projects of Chengdu Rongsheng Pharmaceutical
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2013-2020
Gross Margin of Shuanglin Bio-Pharmacy, 2013-2020
Shuanglin Bio-Pharmacy’s R&D Costs and % of Total Revenue, 2013-2020 
Revenue and Net Income of Guangdong Shuanglin Bio-Pharmacy, 2014-2019
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2019
Production, Inventory and Sales of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2013-2019
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2020
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2020
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2020
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2020
Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2020
Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2020
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2013-2020
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2020
Jiangxi Boya Bio-Pharmaceutical’s R&D Costs and % of Total Revenue, 2013-2020
Production and Sales of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2016-2019
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2020
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2020
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2014-2020
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2020
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2020
Gross Margin of Main Blood Products of Shenzhen Weiguang Biological Products, 2014-2020
Shenzhen Weiguang Biological Products’ R&D Costs and % of Total Revenue, 2014-2020
Progress of Fundraising Projects of Shenzhen Weiguang Biological Products, as of 2020H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2019
Production and Sales of Blood Products of Shenzhen Weiguang Biological Products, 2016-2019
Financial Data of Main Plasma Collection Subsidiaries of Shenzhen Weiguang Biological Products, 2020H1
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2020
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2020
Revenue Breakdown of Beijing Bohui Innovation Technology by Product, 2014-2020
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2020
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2020
Beijing Bohui Innovation Technology’s R&D Costs and % of Total Revenue, 2014-2020
Beijing Bohui Innovation Technology’s Main Ongoing Projects and Their Registration Progress, 2020H1  
Major Blood Products of Beijing Bohui Innovation Technology
Financials of Beijing Bohui Innovation Technology, 2017-2020
Lot Release Volume of Blood Products of Hebei Da’an Pharmaceutical, 2016-2020
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2020
Development Course of Zhongyuan Ruide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2018
Plasma Collection Stations of Wuhan ZhongyuanRuide Biological Products, as of Dec. 2019  
Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2019
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2020
Main Plasma Collection Stations of Shanxi Kangbao Biological Product as of Dec. 2019
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2020
Main Plasma Collection Stations of Green Cross China as of Dec. 2019
Lot Release Volume of Blood Products of Green Cross China, 2016-2020
Main Plasma Collection Stations of Nanyue Biopharming, as of Dec. 2019 
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2020
Market Size of Blood Products in China, 2018-2026E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2020
Plasma Collection Volume of Tiantan Biological Products, 2016-2019
Plasma Collection Volume Structure of Major Companies in China, 2019
Plasma Collection Volume and YoY Change in China, 2019-2026E
R&D Investment of Major Chinese Blood Product Enterprises, 2014-2020
Population Aged above 60 as a Percentage of Total Population in China, 2009-2019 

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号